CoJourney, a global innovator in the manufacturing and development of cell and gene therapies, is pleased to announce the completion of a $30
million Series A financing and expansion of its US organization and commercial manufacturing capabilities. This funding round was led by Legend Holdings and supported by GL Ventures, Legend Star Investment Management and Lake Bleu Capital.

CoJourney is a Contract Manufacturing and Development Organization (CDMO) that serves the product development and manufacturing needs of cell and gene therapy companies globally. The company's services include process development, cGMP production, analytical method development, and QC testing and release for plasmids, viral vectors and mRNAs. CoJourney has built comprehensive offerings include banking, drug substance production and drug product filling, utilizing proprietary platform processes and extensive expertise. The company's cGMP manufacturing processes and state-of-the- art quality systems are robust, scalable, and designed to meet commercial requirements. CoJourney has successfully manufactured products that have been approved by global regulatory agencies, including US FDA, for use in clinical trials. The company employs over 150 scientific and operations staff worldwide.